

Electronic Acknowledgement Receipt

EFS ID:	6182781
Application Number:	10542501
International Application Number:	
Confirmation Number:	5801
Title of Invention:	Quaternary antimuscarinic compounds for the treatment of bladder diseases
First Named Inventor/Applicant Name:	Ronald W Wood
Correspondence Address:	Michael L Goldman Nixon Peabody Clinton Square PO Box 31051 Rochester NY 14603-1051 US - -
Filer:	Michael L. Goldman
Filer Authorized By:	
Attorney Docket Number:	176/61373
Receipt Date:	01-OCT-2009
Filing Date:	10-JAN-2006
Time Stamp:	16:07:04
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$735

RAM confirmation Number	2419				
Deposit Account	141138				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees) Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees) Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees) Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees) Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		20091001_Amendment_176_61373.pdf	123101 3ba3bdc877e88d25d8e2be2b8f57ed3a8e0f4d892	yes	16
	Multipart Description/PDF files in .zip description				
	Document Description		Start		End
	Amendment/Req. Reconsideration-After Non-Final Reject		1		1
	Claims		2		10
	Applicant Arguments/Remarks Made in an Amendment		11		16
Warnings:					
Information:					
2	Extension of Time	20091001_Petition_for_Three_Month_Extension_of_Time_176_61373.pdf	66065 285db87e1e646c5ad74388595f8f3e29c5d45369	no	1
Warnings:					
Information:					
3	Foreign Reference	WO98000133.pdf	1362228 083698bb6d91e11db74eb709d4cc091d7b283	no	30
Warnings:					
Information:					
4	Foreign Reference	WO98000138.pdf	1278121 8c5955be157a7aa513be08bb4b5159482db208	no	29
Warnings:					
Information:					
5	NPL Documents	Abood_The_Psychotomimetic_1968.pdf	1821666 0085eed8ff72668db25c07b1e12111e640053668	no	22

Warnings:					
Information:					
6	NPL Documents	Abood_Anticholinergics_1982.pdf	1233067 a67d23e0ca1948354b1aa283a1b1127910531ab	no	18
Warnings:					
Information:					
7	NPL Documents	Baumgold_Chemical_1975.pdf	842612 226b49e6e6e0e4c15918ab775dc5a3ed77acbc91e	no	9
Warnings:					
Information:					
8	NPL Documents	Baumgold_Studies_1977.pdf	991905 018662c6b71bdcad09122b2bfcdcdc3c7bc9c5	no	10
Warnings:					
Information:					
9	NPL Documents	Bonner_Identification_1987.pdf	609478 db1302a897ab56c4dc42c2cb8f8db86c1183d7ba	no	6
Warnings:					
Information:					
10	NPL Documents	Bonner_Cloning_1988.pdf	625506 7b29c81766f8bc518b3c134294b856159531204	no	8
Warnings:					
Information:					
11	NPL Documents	Brown_Atropine.pdf	1772689 d987383c06ed286671ea11e274ec2f961072eca	no	18
Warnings:					
Information:					
12	NPL Documents	Buckley_Antagonist.pdf	714753 f79f8bc7b66a7b409cfa65393cedf862b754372	no	8
Warnings:					
Information:					
13	NPL Documents	Carroll_Probes.pdf	489048 d17058f54228d7a218151912625534dd67799b	no	5
Warnings:					
Information:					
14	NPL Documents	Carter_Analogues.pdf	1003935 6506c6db675e8f75daa070bc93266205-b050e721	no	10

Warnings:					
Information:					
15	NPL Documents	Cereda_Synthesis.pdf	599792 411ac141c1c9f4c740d406c6b91d4f74077c4b	no	6
Warnings:					
Information:					
16	NPL Documents	Comer_Clocinnamox.pdf	480927 31616610b6cc58f718d2cb094049fda515c4b4b	no	6
Warnings:					
Information:					
17	NPL Documents	Connor_Early.pdf	237954 4802d43b7baf6c5e7b18f827c4c49f6b056a78e	no	3
Warnings:					
Information:					
18	NPL Documents	Davies_Novel.pdf	340531 52992bf3a46c499192b36491196c6c5d737c4f	no	5
Warnings:					
Information:					
19	NPL Documents	Deckers_The_Chemistry.pdf	391725 208ecd55d4d218d1aa36d74b083b46c492b15	no	6
Warnings:					
Information:					
20	NPL Documents	Delforge_Noninvasive_1990.pdf	961957 963d41e947f14f7b4f192184ac00c394f77e13a	no	11
Warnings:					
Information:					
21	NPL Documents	Delforge_Quantification_1993.pdf	915544 71a3bacc812e48857e6e91a1b016597db3820	no	11
Warnings:					
Information:					
22	NPL Documents	Ehlert_The_Quaternary.pdf	537836 15a33973c5d41b4f6641277ac33a58f77c1bc24	no	6
Warnings:					
Information:					
23	NPL Documents	Gibson_The_Distribution.pdf	599508 c09c62e1edee164e16c3c29cc920674cc7029159d	no	6

Warnings:

Information:

24	NPL Documents	Goldstein_Principles.pdf	496902	no	8
			94bf978b9f5d60564a299de7bd15a15a2825a031		

Warnings:

Information:

25	NPL Documents	Gordon_Distance.pdf	548580	no	7
			c6c5d16ec07c42838b8e45c0b5471ba32938ca79ca		

Warnings:

Information:

26	NPL Documents	Griffin_Kinetics.pdf	487207	no	5
			5e6115e4388fd2c7a6077799ad05cae0889b4		

Warnings:

Information:

27	NPL Documents	Gross_Drug.pdf	1068270	no	9
			78c4494dcab87ebba2121143c94c0579089588f11		

Warnings:

Information:

28	NPL Documents	Guan_A_Minipig.pdf	620665	no	7
			00246c9d7c841dc0baef44c2c290bd0941a2c28		

Warnings:

Information:

29	NPL Documents	Haeusler_Drug.pdf	747885	no	14
			112702ab0005a55f4a0418418cb0bf546617dcdc		

Warnings:

Information:

30	NPL Documents	Kaiser_Synthesis_1992.pdf	1036161	no	10
			6a65678bbdd662ef987a0963aba165713c7baac0b		

Warnings:

Information:

31	NPL Documents	Kaiser_Synthesis_1993.pdf	637997	no	7
			2c59a20189e021f97157807d5aac9c2105f0eb19f		

Warnings:

Information:

32	NPL Documents	Kondo_A_Study_Abstract_1993.pdf	389001	no	6
			13b7aebc4081441617dce2eb8e035c3a0952272		

Warnings:					
Information:					
33	NPL Documents	Kondo_Muscarinic_1995.pdf	254559 0c9d88fede5e2c4d8c7ab2b8dc3c5305c d53d8	no	4
Warnings:					
Information:					
34	NPL Documents	Krishnan_A_Double_Abstract. pdf	183338 2dc0d89a00d414017b1d4d48d83d5e8f1 639cf	no	2
Warnings:					
Information:					
35	NPL Documents	Newberry_Pharmacological.pdf	747374 b8dc6e713c0dddbb234158cd9b5c5d0 848b8c5	no	10
Warnings:					
Information:					
36	NPL Documents	Nordvall_Binding.pdf	902583 ew6130d832d5d5f565f8d05c351f42d60 88c3b	no	10
Warnings:					
Information:					
37	NPL Documents	Parsons_Epithelial.pdf	410578 735e3ee77817b73c0523c057d005b48f63 d4d3	no	4
Warnings:					
Information:					
38	NPL Documents	Peterson_Mini.pdf	584772 f100bce1026a8c298061638430d8a547a70 2a5d3	no	9
Warnings:					
Information:					
39	NPL Documents	Roberts_A_Pharmacological. pdf	683384 86a07b2cf4d08a61a2b2978a6c95f5a87b1e 73a9	no	9
Warnings:					
Information:					
40	NPL Documents	Rzesotarski_Analogues.pdf	595612 b7fc5db1f5c3b36365f87c3a10d51d91389 8d96f	no	4
Warnings:					
Information:					
41	NPL Documents	Sebastian_14Beta.pdf	700639 2c6c7183aed667f07c5d9608d8f13ee0493a72 8010	no	7

Warnings:					
Information:					
42	NPL Documents	Sethia_An_Animal.pdf	309270 209ea1d1cc4525998eac34e1a0d8c1b05b91662	no	4
Warnings:					
Information:					
43	NPL Documents	Shishido_Muscarinia_Abstr. pdf	131986 44a5a9ccf81bc39c57d0d0451a1b1c1e03c9a545	no	2
Warnings:					
Information:					
44	NPL Documents	Sternbach_Antispasmodics.pdf	654608 d1c1d4be578bbd02381769c2ad0f0c3ba71016263c	no	4
Warnings:					
Information:					
45	NPL Documents	Thomas_Irreversible.pdf	265756 d2fb3eb3b2d8e3e075e9811c1cae7a71c7b08681	no	5
Warnings:					
Information:					
46	NPL Documents	Waelbroeck_Binding.pdf	667122 8bc1acc9453d202e990c5ac313c20c2b561a08cf	no	8
Warnings:					
Information:					
47	Transmittal Letter	20091001_Supplemental_Infor mation_Disclosure_Statement_ 176_61373.pdf	59644 11c0b00d031e0f745080b44c9122ce5942c8a37	no	1
Warnings:					
Information:					
48	Information Disclosure Statement (IDS) Filed (5B/08)	20091001_PTO_SB_08A_176_6 1373.pdf	129730 0c0a16446597e20a0b5a2401d5d14101927b239	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
49	Fee Worksheet (PTO-875)	fee-info.pdf	31732 6796970313b1c0a48667731a6888942a0c5781	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			31345303		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.